> Details

Decker, Melanie; Agarwal, Anupriya; Benneche, Andreas; Churpek, Jane; Duployez, Nicolas; Duvall, Adam; Ernst, Martijn P. T.; Förster, Alisa; Høberg-Vetti, Hildegunn; Hofmann, Inga; Nash, Michelle; Raaijmakers, Marc H. G. P.; Tvedt, Tor H. A.; Vlachos, Adrianna; Schlegelberger, Brigitte; Illig, Thomas; Ripperger, Tim

Validation and clinical application of transactivation assays forRUNX1variant classification

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Validation and clinical application of transactivation assays forRUNX1variant classification
  • Contributor: Decker, Melanie; Agarwal, Anupriya; Benneche, Andreas; Churpek, Jane; Duployez, Nicolas; Duvall, Adam; Ernst, Martijn P. T.; Förster, Alisa; Høberg-Vetti, Hildegunn; Hofmann, Inga; Nash, Michelle; Raaijmakers, Marc H. G. P.; Tvedt, Tor H. A.; Vlachos, Adrianna; Schlegelberger, Brigitte; Illig, Thomas; Ripperger, Tim
  • Published: American Society of Hematology, 2022
  • Published in: Blood Advances, 6 (2022) 11, Seite 3195-3200
  • Language: English
  • DOI: 10.1182/bloodadvances.2021006161
  • ISSN: 2473-9529; 2473-9537
  • Keywords: Hematology
  • Origination:
  • Footnote:
  • Description: AbstractFamilial platelet disorder with associated myeloid malignancies (RUNX1-familial platelet disorder [RUNX1-FPD]) is caused by heterozygous pathogenic germline variants of RUNX1. In the present study, we evaluate the applicability of transactivation assays to investigate RUNX1 variants in different regions of the protein. We studied 11 variants to independently validate transactivation assays supporting variant classification following the ClinGen Myeloid Malignancies Variant Curation Expert Panel guidelines. Variant classification is key for the translation of genetic findings. We showed that new assays need to be developed to assess C-terminal RUNX1 variants. Two variants of uncertain significance (VUS) were reclassified to likely pathogenic. Additionally, our analyses supported the (likely) pathogenic classification of 2 other variants. We demonstrated functionality of 4 VUS, but reclassification to (likely) benign was challenging and suggested the need for reevaluating current classification guidelines. Finally, clinical utility of our assays was illustrated in the context of 7 families. Our data confirmed RUNX1-FPD suspicion in 3 families with RUNX1-FPD-specific family history, whereas for 3 variants identified in RUNX1-FPD-nonspecific families, no functional defect was detected. Applying functional assays to support RUNX1 variant classification can be essential for adequate care of index patients and their relatives at risk. It facilitates translation of genetic data into personalized medicine.
  • Access State: Open Access